Brought to you by 
Avitide closes Series E round
26 Jun 2017
Executive Summary
Avitide Inc. (affinity purification solutions for biopharma) raised an undisclosed amount in its Series E financing led by Sands Capital Ventures, which adds a board member and was joined by Mithril Capital Management, Polaris Partners, NeoMed Management, OrbiMed Advisors, and Borealis Ventures. The company says the funds will support ongoing operations with the goal of becoming profitable by 2019.
Deal Industry
- Pharmaceuticals
- Services
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Synthesis Technologies, Production Processes
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Avitide closes Series E round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice